3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
12
Thoracic
10
Genitourinary
7
Gynecologic
5
Other solid neoplasm
4
Head & Neck
4
Breast
4
Endocrine
2
Dermatologic
2
Tumor-Agnostic
1
Sarcoma
1
Plasma cell
1
NET
1
Lymphoid
1
CNS
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Esophageal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
342
Rituximab
304
Vincristine
157
Doxorubicin
154
venetoclax
153
fludarabine
153
Specimen Handling
152
Prednisone
150
Biopsy
122
Magnetic Resonance Spectroscopy
117
obinutuzumab
116
Lenalidomide
109
Dexamethasone
104
Cytarabine
97
ibrutinib
95
Etoposide
92
fludarabine phosphate
87
Methotrexate
84
acalabrutinib
78
Bendamustine Hydrochloride
72
zanubrutinib
71
blinatumomab
63
pembrolizumab
62
CT-P10
60
Gemcitabine
51
Nivolumab
45
glofitamab
44
Calcium Dobesilate
44
Mercaptopurine
43
prednylidene
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
zimberelimab
×
Lymphoid
×
1 year
×
Clear all
NCT04772989
2025-08-28
ARC-12
Arcus Biosciences, Inc.
Phase 1
Completed
94 enrolled